home / stock / omga / omga quote
Last: | $2.41 |
---|---|
Change Percent: | -0.42% |
Open: | $2.39 |
Close: | $2.41 |
High: | $2.49 |
Low: | $2.35 |
Volume: | 271,416 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.41 | $2.39 | $2.41 | $2.49 | $2.35 | 271,416 | 05-17-2024 |
$2.38 | $2.28 | $2.38 | $2.4 | $2.24 | 195,264 | 05-16-2024 |
$2.28 | $2.4 | $2.28 | $2.45 | $2.22 | 413,971 | 05-15-2024 |
$2.36 | $2.38 | $2.36 | $2.55 | $2.27 | 426,797 | 05-14-2024 |
$2.355 | $1.98 | $2.355 | $2.52 | $1.98 | 742,178 | 05-13-2024 |
$1.96 | $2.2 | $1.96 | $2.2 | $1.95 | 519,333 | 05-10-2024 |
$2.17 | $2.12 | $2.17 | $2.24 | $2.11 | 292,856 | 05-09-2024 |
$2.145 | $2.15 | $2.145 | $2.16 | $1.96 | 490,498 | 05-08-2024 |
$2.155 | $2.35 | $2.155 | $2.37 | $2.15 | 462,818 | 05-07-2024 |
$2.28 | $2.5 | $2.28 | $2.53 | $2.225 | 578,447 | 05-06-2024 |
$2.58 | $2.83 | $2.58 | $3 | $2.56 | 395,020 | 05-03-2024 |
$2.76 | $2.64 | $2.76 | $2.825 | $2.46 | 695,794 | 05-02-2024 |
$2.48 | $2.25 | $2.48 | $2.59 | $2.25 | 410,403 | 05-01-2024 |
$2.23 | $2.31 | $2.23 | $2.36 | $2.22 | 187,178 | 04-30-2024 |
$2.29 | $2.29 | $2.29 | $2.3562 | $2.26 | 200,712 | 04-29-2024 |
$2.27 | $2.35 | $2.27 | $2.4 | $2.26 | 257,466 | 04-26-2024 |
$2.35 | $2.28 | $2.35 | $2.37 | $2.2001 | 250,249 | 04-25-2024 |
$2.33 | $2.35 | $2.33 | $2.365 | $2.26 | 196,326 | 04-24-2024 |
$2.34 | $2.39 | $2.34 | $2.5399 | $2.32 | 301,171 | 04-23-2024 |
$2.39 | $2.43 | $2.39 | $2.505 | $2.38 | 193,038 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanisms Additional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene exp...
Omega Therapeutics, Inc. (NASDAQ: OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. T...
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024 Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AAC...